NIH R01 · 2024
ABT-199 based therapies to treat neuroblastoma
Project Summary: High-risk neuroblastoma (NB) is responsible for ~13% of pediatric cancer-related deaths. Venetoclax (VEN) is a BCL-2 inhibitor that has revolutionized adult hematological cancer care. Unique among solid tumors, ven has demonstrated promising pre-clinical activity in MYCN-amplified NB, but likely will require rational combinations for clinical activity. In our previous funded work, we have demonstrated VEN makes an effective drug partner across several combination therapies (e.g. Lochmann et al. Science Translational Medicine 2018; Dalton et al. Molecular Cancer Therapeutics 2021). In this renewal application, we focus on two clinically translational combination therapies…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.